BioSpace News Archive

Initiation of Phase 2B Study Follows Quickly After FDA Grants RMAT Designation for Knee OA.

Ms. Wilkinson was presented with the award after her keynote on “Digitising the National Health Service” at the 3rd U.K. CDO Summit in London, England, by CDO Club founder David Mathison.

The report displays the diverse initiatives and growth of companies across Canada; the potential talent to help grow the industry and the positive impact of BioTalent Canada’s many wage subsidy programs on the industry.

Proclara Biosciences, a clinical stage biotechnology company developing novel therapies for diseases caused by protein misfolding, today announced that preclinical data supporting the development of General Amyloid Interaction Motif (GAIM)-based therapies for the treatment of peripheral amyloidoses were presented at the 16th International Symposium on Amyloidosis (ISA) in Kumamoto, Japan.

Abionic AB announced the successful closing of a CHF20 million Series C financing.

Boston Scientific Corporation announced the U.K. Court of Appeal dismissed Edwards Lifesciences’ appeal and upheld a prior court decision that Edwards’ Sapien 3™ device infringes Boston Scientific patent EP (UK) 2 926 766 and that all claims of that patent are valid.

GB Sciences, Inc. is extremely pleased to announce it has signed a letter of intent to purchase 100% of the ownership interests of NevadaPURE’s Las Vegas operation for $28 million in cash and the assumption of approximately $5 million of outstanding liabilities.

Invitae Corporation announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share.

Pivotal trial will enroll approximately 1,400 patients for 12-week treatment period.

Patisiran Demonstrated Improvement of Cardiomyopathy in Prospectively Defined Subgroup of Patients with Cardiac Amyloid Involvement, Relative to Placebo.